Recent Updates
Recently added Catalysts
ABUS

Arbutus to Present at the 2016 Wedbush PacGrow Healthcare Conference

Wednesday, August 10, 2016 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: VANCOUVER, British Columbia and DOYLESTOWN, Pa., Aug. 10, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that the company will be presenting at the Wedbush PacGrow He

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+27%
120-day peak, hindsight
Typical move
2%
average across 5 past catalysts
Cash runway
~46 mo
Minimal dilution risk
Lead asset
TKM-080301
Phase 1 · Cancer

Full Press Release Details

VANCOUVER, British Columbia and DOYLESTOWN, Pa., Aug. 10, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that the company will be presenting at the Wedbush PacGrow Healthcare Conference held August 16-17, 2016 in New York.
Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. Arbutus is headquartered in Vancouver, BC, Canada with offices in Doylestown, PA, USA. For more information, visit www.arbutusbio.com.
ShareAdd on Google
Tags: ABUS Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Aug 10, 2016

Biotech snapshot

Cash runway
$93M liquidity · $2M/mo burn
~46 mo
Minimal dilution risk
Lead asset
TKM-080301Phase 1
Cancer →

Catalyst track record

+27%
best trade around ABUS's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for ABUS.

See every catalyst's timing & PoA →